INmune Bio YTD Return
The INMB YTD return is 7.69% with dividends reinvested through 05/14/2026. Investors often use YTD return to compare year-to-date performance across securities because current calendar year return information is important for tax planning.
This page shows INMB YTD return, annualized return, start and end dates, and the growth of a hypothetical $10,000 investment with dividends reinvested.
| INMB YTD Return Table | ||||||||||||||||||||||||||||||
INMB YTD return is presented with the assumption of reinvestments of any dividends on ex-date. |
| YTD Return Benchmarks |
|
Use our YTD Return Calculator to
compare INMB YTD return versus benchmarks: YTD Return for S&P YTD Return for Dow YTD Return for Nasdaq 100 YTD Return for Russell 2000 YTD Return for Gold YTD Return for 10 Year Treasury |
| INMB Share Performance |
| INMB YTD Return Chart | |||
Also see: INMB Average Annual Return | |||
| About INmune Bio Inc |
| INmune Bio is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient's disease. Co. has two product platforms: dominant-negative tumor necrosis factor, which utilizes dominant-negative technology and is being developed for Alzheimer's and treatment resistant depression and cancer and an out-licensing strategy for Duchenne's Muscular Dystrophy; and Natural Killer Cell Priming Platform, which utilizes a medicine approach for the treatment of a variety of hematologic malignancies, solid tumors and chronic inflammation. The INMB YTD return is shown above.
The YTD Return on the INMB YTD return page and across the coverage universe of our site, is a measure of the total return for a given investment year-to-date for the current calendar year (up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely useful in the context of our country's tax system which taxes gains and income on a calendar year basis. Thus, researching Year-To-Date Returns is good practice for investors — whether INMB YTD return or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the INMB YTD return calculation (with any dividends reinvested as applicable), and to provide a coverage universe of many stocks and ETFs to be able to compare YTD returns. |
| INMB Current Stock Quote |
Quotes delayed 20 minutes  Free INMB Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Don't Forget Dividends in YTD Return! | |
|
| YTD Return Peers |
| INmune Bio (INMB) is categorized under the Healthcare sector; to help you further research YTD return performance across stocks, below are some other companies in the same sector:
INNT YTD Return INNV YTD Return INO YTD Return INSM YTD Return INSP YTD Return INSY YTD Return INTS YTD Return INVA YTD Return INVO YTD Return INZY YTD Return More Healthcare companies » |
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.2%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.2%.
Video: Don't Forget Dividends in YTD Return!